• Explore /
  • Poster
  • / Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had  ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).

Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had  ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).

Abstract Poster

Authors

null

Felicia Roncolato

Macarthur Cancer Therapy Centre, Sydney, Australia

Felicia Roncolato , Florence Joly , Rachel O'Connell , Anne Lanceley , Florian Heitz , Luke Buizen , Aikou Okamoto , Eriko Aotani , Vanda Salutari , Paul P. Donnellan , Amit M. Oza , Elisabeth Avall-Lundqvist , Jonathan S. Berek , Felix Hilpert , Amanda Feeney , Celia Roemer-Becuwe , Martin R. Stockler , Madeleine Trudy King , Michael Friedlander

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

12607000603415

Citation

J Clin Oncol 35, 2017 (suppl; abstr 5575)

DOI

10.1200/JCO.2017.35.15_suppl.5575

Abstract #

5575

Poster Bd #

397

Abstract Disclosures

Similar Posters

First Author: Mansoor Raza Mirza

Poster

2020 ASCO Virtual Scientific Program

Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).

Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).

First Author: Elizabeth M. Swisher

First Author: Jalid Sehouli

First Author: Jonathan Foote